Loading
A phase 3 trial testing PF-08634404 in non-small-cell lung cancer, now recruiting.
SSGJ-707 in Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06980272, led by Shenyang Sunshine Pharmaceutical, and recruiting on the registry. Official title: A Randomised Controlled, Multi-centre Phase III Clinical Trial of SSGJ-707 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 420 participants (estimated). The study started in 2025-06-20 and primary completion is expected in 2026-07-30. No results have been posted on ClinicalTrials.gov.
Shares PF-08634404, Non-small-cell lung cancer.
Shares PF-08634404, Non-small-cell lung cancer.
Shares PF-08634404, Non-small-cell lung cancer.
Shares 3SBio, Non-small-cell lung cancer.
Shares PF-08634404, Non-small-cell lung cancer.
Shares 3SBio, Non-small-cell lung cancer.